Novo released low-dose data for CagriSema during a capital markets day in London as an approval decision looms. The company said the investigational metabolic drug appears competitive with Eli Lilly’s Mounjaro when both are administered at low doses. For investors, low-dose comparative positioning is typically about demonstrating signal consistency before dose-finding and label negotiations become decisive. Even without full efficacy details in the brief item, Novo’s disclosure suggests management is leaning into competitive differentiation ahead of regulatory milestones. The market impact centers on whether regulators accept the comparative narrative around efficacy and tolerability, particularly in populations that may tolerate lower exposure better than standard dosing regimens.